drug
(probenecid + sulopenem etzadroxil)
Marketedupdated 3mo agoby $ITRMF Iterum Therapeutics plc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 3, 2029
~2.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (5)
- Dec 23, 2039formulationUS 11478428
- Dec 23, 2039formulationUS 12544337
- Apr 1, 2039method-of-use (U-4026)US 11554112
- Apr 1, 2039method-of-use (U-4026)US 12109197
- Jun 3, 2029compositionUS 77952432.8y
FDA exclusivities (2)
- Oct 25, 2034GAINGAIN Antibiotic (5y)
- Oct 25, 2029NCENew Chemical Entity (5y)3.2y
News(1)
- Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60%As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 7mo ago
Data sources
last refreshed 59m ago
Found something off?
comments(0)
5-min edit window · permanent after that